Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
7
×
clinical trials
7
×
fda
life sciences
national blog main
boston top stories
national top stories
san francisco blog main
deals
eli lilly
indiana blog main
indiana top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
amgen
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe blog main
europe top stories
investing
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
aimmune therapeutics
akouos
alirocumab
alkermes
What
drug
7
×
fda
7
×
approval
medicines
won
approved
cancer
friday
loss
marketing
medicine
new
therapeutics
treat
weight
acquire
acute
addresses
affects
agency
agreed
aimmune
alkermes
allergy
americans
antipsychotic
awarded
benefits
billion
blueprint
brings
candidate
cash
causes
caveats
cholesterol
commonly
company
compound
condition
Language
unset
7
×
Current search:
drug
×
biotech
×
unset
×
" boston blog main "
×
fda
×
" clinical trials "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds